Onxeo Provides Strategy Update and Reports 2017 Third Quarter Financial Information
October 26, 2017 14:00 ET | Onxeo S.A.
Company completes strategic shift to innovative DNA-targeting programs and platON™ chemistry platform of decoy oligonucleotidesDevelopment of lead product AsiDNATM in line with plans ...
Onxeo Reports First Instance Decision from the Commercial Court of Paris in the Lawsuit against SpeBio/SpePharm
October 17, 2017 16:01 ET | Onxeo S.A.
PARIS, Oct. 17, 2017 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris:ONXEO) (NASDAQ Copenhagen:ONXEO) (FR0010095596), (“Onxeo” or the “Company”), a biotechnology company specializing in the...
Onxeo Introduces platON™, a Proprietary Chemistry Platform of Decoy Oligonucleotides
October 02, 2017 01:00 ET | Onxeo S.A.
PlatON™ will generate new best-in-class DNA-targeting drug candidates starting in 2018In parallel, the Company advances its robust development programs for AsiDNA™ and belinostat, supported by recent...
Onxeo announces compelling preclinical data in combination for its two innovative compounds, AsiDNA™ and belinostat
September 28, 2017 02:00 ET | Onxeo S.A.
Results demonstrate a very strong synergistic effect between AsiDNA™, first-in-class DNA break repair inhibitor (DBRi), and histone deacetylase inhibitors (HDACi)This synergy is particularly high for...
Onxeo Grants Exclusive Worldwide License of Validive® Developed for the Treatment of Oral Severe Mucositis to Monopar Therapeutics
September 13, 2017 02:00 ET | Onxeo S.A.
Agreement includes substantial milestone payments up to $108m as well as escalating royalties on future salesMonopar Therapeutics will drive and fund all remaining development, regulatory and...
Onxeo Announces Top-Line Results from ReLive Phase III Study of Livatag® in Advanced Hepatocellular Carcinoma
September 11, 2017 14:00 ET | Onxeo S.A.
PARIS, Sept. 11, 2017 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris:ONXEO) (NASDAQ Copenhagen:ONXEO), (“Onxeo” or the “Company”), a clinical-stage biotechnology company specializing in the...
Onxeo Announces Positive Preclinical Proof of Concept Results Confirming AsiDNA™ Activity via Systemic Administration
July 05, 2017 01:30 ET | Onxeo S.A.
PARIS, July 05, 2017 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris:ONXEO) (NASDAQ Copenhagen:ONXEO), (“Onxeo” or the “Company”), a clinical-stage biotechnology company specializing in the...
Onxeo Announces 10th Positive DSMB Recommendation to Continue Livatag® ReLive Phase III Trial in HCC
May 23, 2017 12:00 ET | Onxeo S.A.
PARIS, May 23, 2017 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris:ONXEO) (NASDAQ Copenhagen:ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs for...
Onxeo announces allowance of U.S. patent for Livatag® in hepatocellular carcinoma
May 10, 2017 13:17 ET | Onxeo S.A.
PARIS, May 10, 2017 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris:ONXEO) (NASDAQ Copenhagen:ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs for...
Clinigen and Onxeo initiate Managed Access programme for belinostat in Europe for patients with peripheral T-cell lymphoma (PTCL)
April 24, 2017 13:41 ET | Onxeo S.A.
PARIS, April 24, 2017 (GLOBE NEWSWIRE) -- Clinigen Group plc.’s (AIM:CLIN) (‘Clinigen’ or the ‘Group’) Idis Managed Access (MA) division and Onxeo S.A (Euronext Paris:ONXEO) (Nasdaq...